Logo
x

Search

Subscribe Now

All Posts by Date

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

  • February 7, 2022
Active Biotech Reports First Patient Dosing in the P-Ib/IIa Study of Tasquinimod for the Treatment of Multiple Myeloma

Active Biotech Reports First Patient Dosing in the P-Ib/IIa Study of Tasquinimod for the Treatment of Multiple Myeloma

  • February 7, 2022
BioMarin Presents 2-Year Analysis of Valoctocogene Roxaparvovec in P-III (GENEr8-1) Study for Severe Hemophilia A at EAHAD 2022

BioMarin Presents 2-Year Analysis of Valoctocogene Roxaparvovec in P-III (GENEr8-1) Study for Severe Hemophilia A at EAHAD 2022

  • February 7, 2022
Azurity’s Fleqsuvy Receives the US FDA’s Approval for the Treatment of Spasticity Associated with Multiple Sclerosis

Azurity’s Fleqsuvy Receives the US FDA’s Approval for the Treatment of Spasticity Associated with Multiple Sclerosis

  • February 7, 2022
Pfizer and Valneva Report Results of VLA15 in P-II Study for the Treatment of Lyme Disease

Pfizer and Valneva Report Results of VLA15 in P-II Study for the Treatment of Lyme Disease

  • February 7, 2022
Biogen Entered into a Commercialization and License Agreement to Develop & Commercialize Xcimzane, a Proposed Biosimilar Referencing Cimzia (certolizumab pegol)

Biogen Entered into a Commercialization and License Agreement to Develop & Commercialize Xcimzane, a Proposed Biosimilar Referenci...

  • February 7, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.